Celldex Therapeutics (CLDX) said Wednesday that the first patient has been dosed in the company's phase 1a study of CDX-622, a potential inflammatory disease treatment, in healthy volunteers.
The drug is an antibody that targets two complementary pathways that drive inflammatory diseases by neutralizing thymic stromal lymphopoietin and depleting mast cells, the company said.
The phase 1a study aims to assess the safety, pharmacokinetics, and pharmacodynamics of single ascending doses and multiple ascending doses of CDX-622 in up to 56 healthy participants, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments